FOSTER CITY, Calif.--(BUSINESS WIRE)--October 27, 2026--
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report third quarter 2026 financial results on November 3, 2026. Mirum will also host a conference call to discuss the third quarter 2026 financial results and recent corporate progress.
Conference call details:
Tuesday, November 3, 2026
4:30 p.m. ET / 1:30 p.m. PT
Dial-In:
US/Toll-Free: +1 833 461 5787
International: +1 585 542 9983
Access Code: 414267773
You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company's commercial portfolio includes LIVMARLI(R) (maralixibat) for Alagille syndrome $(ALGS)$ and progressive familial intrahepatic cholestasis (PFIC), ATEBRIOZ(TM) (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), CHOLBAM(R) (cholic acid) for bile-acid synthesis disorders and CTEXLI(R) (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum's clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus $(HDV)$ and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome $(FXS)$.
Mirum's success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261027268334/en/
CONTACT: Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Meredith Kiernan
media@mirumpharma.com
Comments